Levosimendan interacts with potassium channel blockers in human saphenous veins

Basic and Clinical Pharmacology and Toxicology

Volumn 94, Issue 6, 2004, Pages 271-273

  Höhn, József ^a   Pataricza, János ^a   Petri, András ^a   Tóth, Gábor K ^a   Balogh, Ádám ^a   Varró, András ^a   Papp, Julius Gy ^a,b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; GLIBENCLAMIDE; IBERIOTOXIN; LEVOSIMENDAN; POTASSIUM CHANNEL; SEROTONIN;

ARTICLE; CHANNEL GATING; CONCENTRATION RESPONSE; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; SAPHENOUS VEIN; SMOOTH MUSCLE RELAXATION; SMOOTH MUSCLE TONE; VASCULAR SMOOTH MUSCLE; VEIN DILATATION;

DRUG INTERACTIONS; GLYBURIDE; HUMANS; HYDRAZONES; PEPTIDES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; PYRIDAZINES; SAPHENOUS VEIN; SEROTONIN; VASODILATION; VASODILATOR AGENTS;

EID: 16744366479     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2004.pto940603.x     Document Type: Article

References (14)

1. + channel opener induced relaxation of the porcine coronary artery. Naunyn-Schmiedebergs Arch. Pharmacol. 1995, 352, 213-221.
2. Follath, F., J. G. F. Cleland, H. Just, J. Gy. Papp, H. Scholz, K. Peuhkurien, V. P. Harjola, V. Mitrovic, M. Abdalla, E.-P. Sandell & L. Lehtonen: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002, 360, 196-202.
3. Gruhn, N., J. E. Nielsen-Kudsk, S. Theilgaard, L. Bang, S. P. Olesen & J. Aldershvile: Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J. Cardiovasc. Pharmacol. 1998, 31, 741-749.
4. Haikala, H., J. Kaivola, E. Nissinen, P. Wall, J. Levijoki & I.-B. Lindén: Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J. Mol. Cell. Cardiol. 1995, 27, 1859-1866.
5. Harkin, C. P., P. S. Pagel, J. P. Tessmer & D. C. Warltier: Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. J. Cardiovasc. Pharmacol. 1995, 26, 179-188.
6. Höhn, J., J. Pataricza, G. K. Tóth, Á. Balogh & J. Gy. Papp: Nitroglycerin activates an iberiotoxin-sensitive potassium channel in human saphenous vein. Acta Physiol. Hung. 1995, 84, 293-294.
7. Latorre, R., A. Oberhauser, P. Labarca & O. Alvarez: Varieties of calcium-activated potassium channels. Annual Rev. Physiol. 1989, 51, 385-399.
8. Nelson, M. T., J. B. Patlak, J. F. Worley & N. B. Standen: Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. Amer. J. Physiol. 1990, 259 (1 Pt 1), C3-C18.
9. Pataricza, J., J. Höhn, A. Petri, Á. Balogh & J. Gy. Papp: Comparison of the vasorelaxant effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J. Pharm. Pharmacol. 2000, 52, 213-217.
10. Pataricza, J., I. Krassói, J. Höhn, A. Kun & J. Gy. Papp: Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine coronary artery. Cardiovasc. Drugs Therap. 2003, 17, 115-121.
11. Sandell, E. P., M. Hayha, S. Antila, P. Heikkinen, P. Ottoila, L. A. Lehtonen & P. J. Pentikainen: Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J. Cardiovasc. Pharmacol. 1995, 26 (Suppl. 1), S57-S62.
12. Udvary, É., J. Gy. Papp & Á. Végh: Cardiovascular effects of the calcium sensitizer levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction. Brit. J. Pharmacol. 1995, 114, 656-661.
13. + channel in rat arterial myocytes. Eur. J. Pharmacol. 1997, 333, 249-259.
14. Yokoshiki, H. & N. Sperelakis: Vasodilating mechanism of levosimendan. Cardiovasc. Drugs Therap. 2003, 17, 111-113.